Page 3 - Apeiron Bioenergy Raises News Today : Breaking News, Live Updates & Top Stories | Vimarsana

APEIRON Biologics AG: APEIRON Biologics APN01 Selected for Large-Scale US Trial in COVID-19
APEIRON s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS
Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue
Additional pre-clinical data show highly promising results with APN01 in various mutation variants
Financing round planned to secure funding of further upcoming development steps
VIENNA, AUSTRIA / ACCESSWIRE / May 19, 2021 / APEIRON Biologics AG announced today the next development steps for APN01 (alunacedase alfa) for the treatment of COVID-19. Based on the recently announced clinical results from APEIRON s Phase 2 trial with APN01 in COVID-19, APN01 will be developed in further international clinical trials with different COVID-19 patient populations and drug delivery routes. ....

United Kingdom , South Africa , South African , Julia Hofmann , Kostenloser Wertpapierhandel , Romana Gugenberger , Sean Collins , Peter Llewellyn Davies , Andreas Jungfer , Pharma Ltd , Mc Services , Collaborative Network Of Networks , Vanderbilt Institute For Clinical , National Heart Lung , United State National Institutes Of Health , Emergency Medicine At Vanderbilt University Medical Center , Translational Research , Blood Institute , United State National Institutes , Collaborative Network , Renin Angiotensin Aldosterone System , Chief Executive Officer , Emergency Medicine , Vanderbilt University Medical Center , Chronic Obstructive Pulmonary Disease , Pulmonary Arterial Hypertension ,